The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F COVER PAGE

OMB APPROVAL
OMB Number: 3235-0006
Expires: July 31, 2015
Estimated average burden
hours per response: 23.8

Report for the Calendar Year or Quarter Ended: 06-30-2022
Check here if Amendment   Amendment Number:
This Amendment (Check only one.):   is a restatement.
  adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: COMMODORE CAPITAL LP
Address: 767 FIFTH AVE
12TH FLOOR
NEW YORK , NY10153
Form 13F File Number: 028-20976

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:
Name: Michael Kramarz
Title: Managing Partner
Phone: 917-970-1730
Signature, Place, and Date of Signing:
Michael Kramarz New York , NY 08-15-2022
[Signature] [City, State] [Date]
Report Type (Check only one.):
X 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)
  13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)
  13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)
Form 13F Summary Page
Report Summary:
Number of Other Included Managers: 0
Form 13F Information Table Entry Total: 24
Form 13F Information Table Value Total: 472,974
(thousands)
List of Other Managers Reporting for this Manager:
[If there are no entries in this list, omit this section.]
Form 13F File Number Name

List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
[If there are no entries in this list, state “NONE” and omit the column headings and list entries.]
No. Form 13F File Number Name


SEC FORM 13F-HR

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Expires: July 31, 2015
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ACLARIS THERAPEUTICS INC COM 00461U105 33,652 2,410,622 SH SOLE 2,410,622 0 0
ARROWHEAD PHARMACEUTICALS IN COM 04280A100 11,004 312,533 SH SOLE 312,533 0 0
BCLS ACQUISITION CORP COM CL A G0904B105 2,475 250,000 SH SOLE 250,000 0 0
BELLUS HEALTH INC NEW COM NEW 07987C204 41,393 4,479,784 SH SOLE 4,479,784 0 0
CELCUITY INC COM 15102K100 8,376 920,464 SH SOLE 920,464 0 0
CELLDEX THERAPEUTICS INC NEW COM NEW 15117B202 14,526 538,812 SH SOLE 538,812 0 0
COGENT BIOSCIENCES INC COM 19240Q201 44,601 4,944,708 SH SOLE 4,944,708 0 0
CYMABAY THERAPEUTICS INC COM 23257D103 16,929 5,738,500 SH SOLE 5,738,500 0 0
CYTOKINETICS INC COM NEW 23282W605 35,111 893,646 SH SOLE 893,646 0 0
DAY ONE BIOPHARMACEUTICALS I COM 23954D109 13,240 739,661 SH SOLE 739,661 0 0
IMMUNIC INC COM 4525EP101 3,099 893,013 SH SOLE 893,013 0 0
INVENTIVA SA ADS 46124U107 995 175,500 SH SOLE 175,500 0 0
IVERIC BIO INC COM 46583P102 23,184 2,409,961 SH SOLE 2,409,961 0 0
KALVISTA PHARMACEUTICALS INC COM 483497103 3,076 312,553 SH SOLE 312,553 0 0
KARYOPHARM THERAPEUTICS INC COM 48576U106 8,730 1,935,609 SH SOLE 1,935,609 0 0
KURA ONCOLOGY INC COM 50127T109 33,480 1,826,491 SH SOLE 1,826,491 0 0
MERUS N V COM N5749R100 59,221 2,615,762 SH SOLE 2,615,762 0 0
REZOLUTE INC COM NEW 76200L309 3,908 1,210,000 SH SOLE 1,210,000 0 0
SATSUMA PHARMACEUTICALS INC COM 80405P107 15,365 3,711,286 SH SOLE 3,711,286 0 0
TENAYA THERAPEUTICS INC COM 87990A106 2,014 357,699 SH SOLE 357,699 0 0
TRICIDA INC COM 89610F101 19,635 2,028,453 SH SOLE 2,028,453 0 0
VIRIDIAN THERAPEUTICS INC COM 92790C104 18,959 1,638,609 SH SOLE 1,638,609 0 0
VISTAGEN THERAPEUTICS INC COM NEW 92840H202 11,483 13,049,079 SH SOLE 13,049,079 0 0
XENON PHARMACEUTICALS INC COM 98420N105 48,518 1,594,932 SH SOLE 1,594,932 0 0